125 related articles for article (PubMed ID: 30539696)
1. Cystathionine β-synthase Induces Multidrug Resistance and Metastasis in Hepatocellular Carcinoma.
Wang L; Han H; Liu Y; Zhang X; Shi X; Wang T
Curr Mol Med; 2018; 18(7):496-506. PubMed ID: 30539696
[TBL] [Abstract][Full Text] [Related]
2. Role of the cystathionine β-synthase/H2S system in liver cancer cells and the inhibitory effect of quinolone-indolone conjugate QIC2 on the system.
Jia H; Ye J; You J; Shi X; Kang W; Wang T
Oncol Rep; 2017 May; 37(5):3001-3009. PubMed ID: 28440458
[TBL] [Abstract][Full Text] [Related]
3. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
Yu M; Zou Q; Wu X; Han G; Tong X
Biomed Pharmacother; 2017 Nov; 95():1844-1852. PubMed ID: 28968929
[TBL] [Abstract][Full Text] [Related]
4. Blocking Endogenous H
Zhang H; Song Y; Zhou C; Bai Y; Yuan D; Pan Y; Shao C
Radiat Res; 2018 Oct; 190(4):374-384. PubMed ID: 30016218
[TBL] [Abstract][Full Text] [Related]
5. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
6. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
7. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
8. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
[TBL] [Abstract][Full Text] [Related]
9. Efflux inhibition by H
Stokes E; Shuang T; Zhang Y; Pei Y; Fu M; Guo B; Parissenti A; Wu L; Wang R; Yang G
Life Sci; 2018 Nov; 213():116-125. PubMed ID: 30343125
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Mediates the Reversal Effect of Verapamil on Chemo-Resistance to Adriamycin of Hepatocellular Carcinoma.
Yang G; Fan G; Zhang T; Ma K; Huang J; Liu M; Teng X; Xu K; Fan P; Cheng D
Med Sci Monit; 2018 Apr; 24():2072-2082. PubMed ID: 29627846
[TBL] [Abstract][Full Text] [Related]
11. Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis.
Zhou YF; Song SS; Tian MX; Tang Z; Wang H; Fang Y; Qu WF; Jiang XF; Tao CY; Huang R; Zhou PY; Zhu SG; Zhou J; Fan J; Liu WR; Shi YH
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413167
[TBL] [Abstract][Full Text] [Related]
12. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucosedependent alterations in reactive oxygen species, P-glycoprotein and DKK4.
Chouhan S; Singh S; Athavale D; Ramteke P; Vanuopadath M; Nair BG; Nair SS; Bhat MK
J Biosci; 2020; 45():. PubMed ID: 32713860
[TBL] [Abstract][Full Text] [Related]
14. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
Ma Z; Guo D; Wang Q; Liu P; Xiao Y; Wu P; Wang Y; Chen B; Liu Z; Liu Q
Theranostics; 2019; 9(10):2967-2983. PubMed ID: 31244936
[TBL] [Abstract][Full Text] [Related]
15. Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.
Carabias P; Espelt MV; Bacigalupo ML; Rojas P; Sarrias L; Rubin A; Saffioti NA; Elola MT; Rossi JP; Wolfenstein-Todel C; Rabinovich GA; Troncoso MF
Cell Death Dis; 2022 Jan; 13(1):79. PubMed ID: 35075112
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1.
Yang Y; Zhang J; Wu T; Xu X; Cao G; Li H; Chen X
Life Sci; 2019 Jan; 216():200-206. PubMed ID: 30465789
[TBL] [Abstract][Full Text] [Related]
17. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
18. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein.
Xiang QF; Zhang DM; Wang JN; Zhang HW; Zheng ZY; Yu DC; Li YJ; Xu J; Chen YJ; Shang CZ
Liver Int; 2015 Mar; 35(3):1010-23. PubMed ID: 24621440
[TBL] [Abstract][Full Text] [Related]
20. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
